Purchase Order 75N92022P00046

This is a firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The $102,100 contract is for testing 10 novel small molecule compounds against a panel of 50 wild-type kinases, as well as testing 5 compounds against a more comprehensive panel of 374 wild-type kinases. The purpose is to assess the kinase...

This $29,376 firm-fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The award is to obtain kinase hotspot assay compound testing services from Reaction Biology. This contract is not associated with a larger vehicle. The purpose is to test 120 novel small molecule compounds for inhibitory activity...

This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Activx Biosciences, Inc., a foreign-owned for-profit organization. The $180,600 contract is for kinase profiling services, with a completion date of November 29, 2022. Activx Biosciences has previously provided similar drug discovery and profiling services to other NIH entities such as the National Cancer Institute...

This $125,600.00 firm fixed-price purchase order was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business, to conduct testing of novel small molecule compounds for kinase inhibition. The contract does not have a set-aside designation. The work involves screening 300 compounds against 3 wild-type kinases and 10 compounds against a panel of 50 wild-type kinases using...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $24,950 purchase order to Enzymlogic SL of Spain. Under the firm fixed price contract, Enzymlogic will conduct profiling of nine BTK inhibitors versus the active and inactive form of the enzyme from August 21, 2023 through December 22, 2023. The contract supports the National Institutes of Health's efforts to advance biomedical research and development by...

This is a firm fixed-price purchase order awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The $21,027.68 contract is for the testing of 2 compounds against a selected kinase panel in a biochemical gamma 33P-ATP kinase assay. Reaction Biology specializes in enzyme activity assays and has previously provided kinase inhibition testing, cancer cell line screening, and...

This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Reaction Biology Corporation, a self-certified small disadvantaged business. The $143,260.00 contract is for kinase screening services, with Reaction Biology testing 377 wild-type kinases against 10 compounds. The award stems from a non-competitive solicitation issued by the NIH's National Center for Advancing Translational...

This federal contract award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), was issued to Reaction Biology Corporation, a self-certified small disadvantaged business based in Malvern, PA. The $150,330 firm-fixed-price purchase order contract requires Reaction Biology to provide compound testing services, including screening 10 small molecule compounds against a panel of 50 kinases and 5 compounds against a panel of 374 kinases using the Kinase...

This is a $20,823.14 firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Eurofins Discoverx LLC, a foreign-owned for-profit organization. The purpose is to test 30 compounds for binding to IRAK and FLT3 kinases over a 1-year period of performance from September 16, 2020 to September 15, 2021. This award was made through a non-competitive combined synopsis/solicitation process under simplified acquisition procedures...

This firm fixed price purchase order awards Enamine LTD $230,323.60 to provide the National Center for Advancing Translational Sciences two general GPCR libraries totaling 27,000 compounds at $5.20 per compound. The libraries will support the National Institutes of Health's National Institute on Drug Abuse in identifying and developing novel small molecule leads against human disease targets through screening of thousands of compounds. One library will contain a minimum of 25,000 general GPCR...